{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:22:42Z","timestamp":1789662162094,"version":"4.0.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chemotherapy-induced thrombocytopenia (CIT) is a challenge in cancer treatment, increasing bleeding risks and reducing chemotherapy dose. We sought to compare the efficacy and safety of various treatments for CIT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Randomized controlled trials (RCTs) involving CIT treatments were subjected to a systematic review and network meta-analysis. PubMed, Embase, Web of Science, Cochrane Library, and <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> databases were searched up to 2 July 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixteen RCTs (<jats:italic>n<\/jats:italic> = 1,746) were included in this study. Pairwise meta-analysis showed thrombopoietic agents significantly reduced platelet transfusions (OR = 0.50; 95% CI: 0.32\u20130.77), improved nadir platelet count (SMD = 0.39; 95% CI: 0.25\u20130.53) and promoted platelet recovery \u2265100 \u00d7 10<jats:sup>9<\/jats:sup>\/L (SMD = \u22120.48; 95% CI: \u22120.68 to \u22120.28). Thrombopoietin receptor agonists (TPO-RAs) reduced chemotherapy delays or dose reductions (OR = 0.37; 95% CI: 0.20\u20130.67) and the incidence of grade 3\/4 thrombocytopenia (OR = 0.50; 95% CI: 0.27\u20130.93). Network meta-analysis indicated that eltrombopag ranked first in reducing chemotherapy dose reductions or delays and increasing nadir platelet count. In terms of reducing the incidence of grade 3\/4 thrombocytopenia, recombinant human thrombopoietin (rhTPO) ranked highest, followed by eltrombopag. Recombinant human interleukin-11 (rhIL-11) had the lowest platelet transfusion rate but the highest incidence of adverse events, whereas avatrombopag had the lowest rate of adverse events and thromboembolism. Additionally, avatrombopag outperformed eltrombopag in promoting hemoglobin and neutrophils recovery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Thrombopoietic agents may benefit CIT patients. TPO-RAs, particularly eltrombopag, show superior efficacy and good tolerability. Although rhIL-11 and rhTPO can rapidly promote platelet recovery and reduce platelet transfusions, they have several limitations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration:<\/jats:title><jats:p><jats:ext-link>https:\/\/inplasy.com\/inplasy-2024-11.0105\/<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1549214","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:29:47Z","timestamp":1753162187000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of different treatments in chemotherapy-induced thrombocytopenia: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Huiyan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaokun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejphar.2010.09.072","article-title":"Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist","volume":"650","author":"Abe","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet. Haematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood-2018-11-884486","article-title":"Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-\u03b3","volume":"133","author":"Alvarado","year":"2019","journal-title":"Blood"},{"key":"B5","first-page":"437","article-title":"A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor","volume":"26","author":"Bai","year":"2004","journal-title":"Zho\u0304nggu\u00f3 yi\u0304xu\u00e9 ke\u0304xu\u00e9yua\u0300n xu\u00e9ba\u0300o"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/DDDT.S299591","article-title":"A review of romiplostim mechanism of action and clinical applicability","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"B7","first-page":"318+319","article-title":"Comparison of effect between rhTPO and rhIL-11 on treatment for cancer patients with thrombocytopenia","volume":"3","author":"Chen","year":"2010","journal-title":"J. Pract. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","article-title":"Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis","volume":"134","author":"Dafni","year":"2019","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.4161\/cc.10.10.15619","article-title":"Thrombopoietin and hematopoietic stem cells","volume":"10","author":"de Graaf","year":"2011","journal-title":"Cell Cycle"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.v85.9.2347.bloodjournal8592347","article-title":"Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study","volume":"85","author":"D'Hondt","year":"1995","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"180119","DOI":"10.1183\/16000617.0119-2018","article-title":"Cancer-associated thrombosis: the when, how and why","volume":"28","author":"Fernandes","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(18)30231-X","article-title":"Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study","volume":"6","author":"Frey","year":"2019","journal-title":"Lancet Haematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"Gilreath","year":"2021","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/blood.v87.9.3615.bloodjournal8793615","article-title":"A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy","volume":"87","author":"Gordon","year":"1996","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3109\/10428194.2012.713477","article-title":"A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine","volume":"54","author":"Greenberg","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nm.3770","article-title":"The ashwell-morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling","volume":"21","author":"Grozovsky","year":"2015","journal-title":"Nat. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/rheumatology\/key119","article-title":"Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists","volume":"57","author":"Guitton","year":"2018","journal-title":"Rheumatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ-British Med. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1200\/JCO.1997.15.11.3368","article-title":"Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin","volume":"15","author":"Isaacs","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00228-020-02960-7","article-title":"Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters","volume":"76","author":"Katsube","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B23","first-page":"265","article-title":"Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice","volume":"24","author":"Kaushansky","year":"1996","journal-title":"Exp. Hematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"10","author":"Kellum","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1046\/j.1537-2995.2002.00056.x","article-title":"Whatever happened to thrombopoietin?","volume":"42","author":"Kuter","year":"2002","journal-title":"Transfusion"},{"key":"B27","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.blre.2021.100909","article-title":"The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag","volume":"53","author":"Kuter","year":"2022","journal-title":"Blood Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","article-title":"Recombinant human thrombopoietin: basic biology and evaluation of clinical studies","volume":"100","author":"Kuter","year":"2002","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/jep.13152","article-title":"Efficacy and safety of recombinant human interleukin-11 in the treatment of acute leukaemia patients with chemotherapy-induced thrombocytopenia: a systematic review and meta-analysis","volume":"26","author":"Liu","year":"2020","journal-title":"J. Eval. Clin. Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.17808","article-title":"A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients","volume":"195","author":"Mei","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3332\/ecancer.2019.906","article-title":"Younger age and previous exposure to radiation therapy are correlated with the severity of chemotherapy-induced thrombocytopenia","volume":"13","author":"Mkhitaryan","year":"2019","journal-title":"eCancerMedicalScience"},{"key":"B33","doi-asserted-by":"publisher","first-page":"103653","DOI":"10.1016\/j.critrevonc.2022.103653","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients","volume":"174","author":"Murphy","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fendo.2017.00234","article-title":"Genetic alterations of the Thrombopoietin\/MPL\/JAK2 axis impacting megakaryopoiesis","volume":"8","author":"Plo","year":"2017","journal-title":"Front. Endocrinol."},{"key":"B35","first-page":"221","article-title":"Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia","volume":"1","author":"Profit","year":"2006","journal-title":"Core Evid."},{"key":"B36","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.17140","article-title":"Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia","volume":"193","author":"Quintino","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1182\/blood-2011-12-399667","article-title":"Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation","volume":"120","author":"Roth","year":"2012","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0257673","DOI":"10.1371\/journal.pone.0257673","article-title":"Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia","volume":"17","author":"Soff","year":"2022","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/17474086.2023.2201428","article-title":"Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia","volume":"16","author":"Song","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"B42","first-page":"892","article-title":"Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia","volume":"21","author":"Sun","year":"2002","journal-title":"Ai zheng = Aizheng = Chin. J. cancer"},{"key":"B43","first-page":"3607","article-title":"A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy","volume":"87","author":"Tepler","year":"1996","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood-2020-141290","article-title":"A phase 3 randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of avatrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"136","author":"Tian","year":"2020","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"100774","DOI":"10.1016\/j.blre.2020.100774","article-title":"Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients","volume":"47","author":"van Dijk","year":"2021","journal-title":"Blood Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fendo.2017.00059","article-title":"The thrombopoietin receptor: structural basis of traffic and activation by ligand, mutations, agonists, and mutated calreticulin","volume":"8","author":"Varghese","year":"2017","journal-title":"Front. Endocrinol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/bbmt.1998.v4.pm9923411","article-title":"A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer","volume":"4","author":"Vredenburgh","year":"1998","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B48","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int. J. Hematol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/cam4.326","article-title":"Eltrombopag with gemcitabine\u2010based chemotherapy in patients with advanced solid tumors: a randomized phase I study","volume":"4","author":"Winer","year":"2015","journal-title":"Cancer Med. (Malden, MA)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00520-011-1290-x","article-title":"Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy","volume":"20","author":"Wu","year":"2012","journal-title":"Support. Care Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","article-title":"Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007","volume":"31","author":"Wu","year":"2009","journal-title":"Clin. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1111\/jcmm.13809","article-title":"Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist","volume":"22","author":"Xie","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.7150\/jca.26690","article-title":"A randomized controlled study of rhTPO and rhIL-11 for the prophylactic treatment of chemotherapy-induced thrombocytopenia in non-small cell lung cancer","volume":"9","author":"Xu","year":"2018","journal-title":"J. Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","article-title":"Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche","volume":"1","author":"Yoshihara","year":"2007","journal-title":"Cell Stem Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/bjh.17510","article-title":"Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia","volume":"194","author":"Yu","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"CD012035","DOI":"10.1002\/14651858.CD012035.pub2","article-title":"Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours","volume":"11","author":"Zhang","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B58","first-page":"12125","article-title":"Efficacy and safety of recombinant human interlerukin-11 in the treatment of chemotherapy-induced thrombocytopenia in acute lymphoblastic leukemia","volume":"6","author":"Zhou","year":"2016","journal-title":"Int. J. Clin. Exp. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1549214\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:29:49Z","timestamp":1753162189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1549214\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":58,"alternative-id":["10.3389\/fphar.2025.1549214"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1549214","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"article-number":"1549214"}}